Alopecia de patrón femenino: causas, clasificación y tratamiento

Female pattern hair loss (FPHL), also known as androgenetic alopecia in women, is a progressive condition driven by a combination of genetic predisposition and hormonal factors:

• Genetic susceptibility: FPHL is polygenic, involving multiple genes that affect hair follicle sensitivity to androgens. Having a first-degree relative with hair loss increases risk by 3-4x.
• Hormonal influence: While androgens (particularly DHT) play a role, FPHL can occur in women with normal androgen levels. The condition often worsens after menopause when estrogen's protective effect on hair follicles diminishes.
• Follicular miniaturization: Over time, affected follicles produce progressively thinner, shorter, less pigmented hairs until the follicle eventually stops producing visible hair.

The Ludwig classification system describes three stages:

• Stage I: Mild thinning along the part line, barely noticeable
• Stage II: Moderate thinning with widening of the central part, scalp becoming visible
• Stage III: Advanced diffuse thinning across the crown, significant scalp visibility

Unlike male pattern baldness, women typically retain their frontal hairline and rarely progress to complete baldness. Early detection through regular scalp photography can help track progression.

Evidence-based treatments for FPHL include both topical and systemic options:

First-line treatments:

• Minoxidil 5% (topical): The only FDA-approved treatment for FPHL. A 2022 meta-analysis in the Journal of the American Academy of Dermatology found 5% minoxidil superior to 2%, increasing hair count by 18-26 hairs per cm² over 6 months. Must be used continuously.
• Oral minoxidil (low-dose): Emerging evidence supports 0.25-2.5mg oral minoxidil daily. A 2022 study in JAAD found it comparable to topical with fewer scalp side effects, though it may cause mild generalized hypertrichosis (facial hair growth) in some women.

Second-line treatments:

• Spironolactone: An anti-androgen typically prescribed at 100-200mg daily. A 2020 retrospective study found 74% of women reported improvement after 12 months. Not FDA-approved for hair loss; used off-label.
• PRP (platelet-rich plasma): Monthly injections for 3-4 sessions, then maintenance every 6-12 months. A 2019 meta-analysis found significant improvement in hair density in most studies.

Upload your scalp photos or dermatologist reports to WAYJET's Medical Report Analyzer for an AI assessment of treatment options based on your specific pattern and severity.

While medical treatments are the cornerstone, several modifiable factors can optimize results:

• Correct nutritional deficiencies: Iron (ferritin below 30 ng/mL is associated with increased shedding), vitamin D (aim for 40-60 ng/mL), zinc, and biotin deficiencies all contribute to hair loss. A 2019 review in Dermatology and Therapy recommended checking ferritin, vitamin D, zinc, and thyroid function in all women with FPHL.
• Stress management: Chronic stress can trigger telogen effluvium that compounds FPHL. A 2021 study in Nature identified the specific mechanism: stress hormones directly inhibit hair follicle stem cell activation.
• Scalp care: Gentle handling, avoiding tight hairstyles, and minimizing heat styling reduce mechanical damage to already vulnerable hair. Scalp massage (4 minutes daily) showed increased hair thickness in a small 2016 study in ePlasty.
• Supplement considerations: Viviscal (marine protein supplement) showed a 32% increase in terminal hair count over 6 months in a 2015 randomized trial. Nutrafol has shown improvement in hair growth markers in several clinical studies.

Consistency is critical with any treatment — most regimens require 6-12 months to show results, and discontinuation of minoxidil leads to resumption of hair loss within 3-6 months.